On the morning of March 18, a ground-breaking ceremony was held for the Business Center of SPH Changzhou Pharma. With a gross floor area of over 55,000 ㎡, the Center will have two high-rises and five annex buildings. It is designed to be a multi-functional industrial carrier, serving as office space, an R&D center, and an incubation accelerator. The Center, whose construction is due to be completed by December 2022, marks the largest single building project in the history of SPH Changzhou Pharma.

Headquartered in Shanghai, the Shanghai Pharmaceuticals Holding Co. Ltd. (SPH) is a vertically-integrated and diversified pharmaceutical group. In 2019, SPH reported revenues of US$26.5bn, ranking among Fortune Global 500 Companies. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. Changzhou Pharmaceuticals (Changzhou Pharma) is one of the core subsidiaries of SPH. With a history of 67 years, it provides leading health care services in R&D, manufacturing, distribution and retail.

掃一掃在手機打開當前頁